Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor– and Interleukin-17–Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis

Arthritis and Rheumatology

Volumn 69, Issue 12, 2017, Pages 2283-2291

  Fleischmann, Roy M ^a   Wagner, Frank ^b   Kivitz, Alan J ^c   Mansikka, Heikki T ^d   Khan, Nasser ^d   Othman, Ahmed A ^d   Khatri, Amit ^d   Hong, Feng ^d   Jiang, Ping ^d   Ruzek, Melanie ^d   Padley, Robert J ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Altoona Center for Clinical Research   (United States)

^d ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CCL23 CHEMOKINE; CORTICOSTEROID; CXCL1 CHEMOKINE; CXCL9 CHEMOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12P40; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 6 RECEPTOR; MACROPHAGE DERIVED CHEMOKINE; METHOTREXATE; PLACEBO; REMTOLUMAB; STEM CELL FACTOR; STROMELYSIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; ABT-122; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; BETA CHEMOKINE; CCL23 PROTEIN, HUMAN; CXCL10 PROTEIN, HUMAN; CXCL9 PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; IMMUNOGLOBULIN; TNF PROTEIN, HUMAN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HERPES SIMPLEX; HUMAN; INFECTION; INJECTION SITE REACTION; MALE; PHARMACODYNAMICS; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CHEMOKINES, CC; DOUBLE-BLIND METHOD; E-SELECTIN; FEMALE; HUMANS; IMMUNOGLOBULINS; INTERLEUKIN-17; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85034023343     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40319     Document Type: Article

References (39)

1. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1–26.
2. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3–15.
3. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509.
4. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012;51 Suppl 5:v3–11.
5. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998;161:409–14.
6. Chabaud M, Miossec P. The combination of tumor necrosis factor α blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 2001;44:1293–303.
7. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther 2011;13:R126.
8. Hull DN, Williams RO, Pathan E, Alzabin S, Abraham S, Taylor PC. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis. Clin Exp Immunol 2015;181:401–6.
9. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023–38.
10. Cremonesi E, Amicarella F, Padovan E, Muraro MG, Mele V, Zajac P, et al. Chemotactic factors underlying tumor infiltration by immunocompetent cells in colorectal cancer [abstract]. Cancer Res 2015;75 Suppl 15:1275.
11. Kakimi K, Lane TE, Wieland S, Asensio VC, Campbell IL, Chisari FV, et al. Blocking chemokine responsive to γ-2/interferon (IFN)-γ inducible protein and monokine induced by IFN-γ activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001;194:1755–66.
12. Laragione T, Brenner M, Sherry B, Gulko PS. CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis. Arthritis Rheum 2011;63:3274–83.
13. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2014;13:272–80.
14. Kuan WP, Tam LS, Wong CK, Ko FW, Li T, Zhu T, et al. CXCL 9 and CXCL 10 as sensitive markers of disease activity in patients with rheumatoid arthritis. J Rheumatol 2010;37:257–64.
15. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 2014;32:659–702.
16. Patel VP, Kreider BL, Li Y, Li H, Leung K, Salcedo T, et al. Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med 1997;185:1163–72.
17. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 2008;58:2257–67.
18. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
19. Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992;77:543–9.
20. Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998;50:197–263.
21. Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 2009;38:439–44.
22. Cuff C, Hsieh CM, Mathieu S, Murtaza A, Hugunin M, Bryant S, et al. Dual neutralization of TNF and IL-17 provides greater efficacy in collagen induced arthritis through regulation of a gene transcription program that includes CXCL1 and CXCL5 [abstract]. Arthritis Rheumatol 2013;65 Suppl 10:S406.
23. Cuff C, Bryant S, Hugunin M, Kamath R, Voss J, Olson L, et al. Dual neutralization of TNF and IL-17 with a DVD-Ig protein is efficacious in collagen induced arthritis [abstract]. Ann Rheum Dis 2014;73 Suppl 2:363.
24. Hsieh CM, Cuff C, Tarcsa E, Hugunin M. Discovery and characterization of ABT-122, an anti-TNF/IL-17 DVD-IG™ molecule as a potential therapeutic candidate for rheumatoid arthritis [abstract]. Ann Rheum Dis 2014;73 Suppl 2:495.
25. Khatri A, Goss S, Jiang P, Mansikka H, Othman AA. Pharmacokinetics of ABT-122, a TNFα- and IL-17A-targeted dual-variable domain immunoglobulin, in healthy subjects and patients with rheumatoid arthritis: results from three phase I trials. Clin Pharmacokinet 2017. E-pub ahead of print.
26. Mansikka H, Ruzek M, Hugunin M, Ivanov A, Brito A, Clabbers A, et al. Safety, tolerability, and functional activity of ABT-122, a dual TNF- and IL-17A–targeted DVD-IG™, following single-dose administration in healthy subjects [abstract]. Ann Rheum Dis 2015;74 Suppl 2:482–3.
27. Fleischmann R, Wagner F, Kivitz AJ, Mansikka HT, Khan N, Liu J, et al. Safety, tolerability, and pharmacodynamics of ABT-122, a dual TNF- and IL-17-targeted dual variable domain (DVD)-IgTM in subjects with rheumatoid arthritis [abstract]. Arthritis Rheumatol 2015;67 Suppl 10. URL: http://acrabstracts.org/abstract/safety-tolerability-and-pharmacodynamics-of-abt-122-a-dual-tnf-and-il-17-targeted-dual-variable-domain-dvd-igtm-in-subjects-with-rheumatoid-arthritis/.
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
29. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
30. Fleischmann R, van der Heijde D, Koenig AS, Pedersen R, Szumski A, Marshall L, et al. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index? Ann Rheum Dis 2015;74:1132–7.
31. Eriksson C, Rantapaa-Dahlqvist S, Sundqvist KG. Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 2013;42:260–5.
32. Tarrant TK, Patel DD. Chemokines and leukocyte trafficking in rheumatoid arthritis. Pathophysiology 2006;13:1–14.
33. Mellado M, Martinez-Munoz L, Cascio G, Lucas P, Pablos JL, Rodriguez-Frade JM. T cell migration in rheumatoid arthritis. Front Immunol 2015;6:384.
34. Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum 2011;63:622–32.
35. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412–9.
36. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007;66:228–34.
37. Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, et al. A phase II randomized study of subcutaneous ixekizumab, an anti–interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 2014;66:1693–704.
38. Pavelka K, Chon Y, Newmark R, Lin SL, Baumgartner S, Erondu N. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol 2015;42:912–9.
39. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013;72:863–9.